BioLife Solutions found using ticker (BLFS) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 55 and 35.5 with a mean TP of 43.5. Now with the previous closing price of 39.89 this would indicate that there is a potential upside of 9.0%. The 50 day MA is 38.54 and the 200 moving average now moves to 27.27. The company has a market capitalisation of $1,382m. Find out more information at: http://www.biolifesolutions.com
BioLife Solutions develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions was founded in 1987 and is headquartered in Bothell, Washington.